4D Molecular Therapeutics(FDMT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents • 4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of succe ...